To include your compound in the COVID-19 Resource Center, submit it here.

June 24 Company Quick Takes: Terns gains Chinese rights to elafibranor; plus venetoclax, Zejula and more

Terns gets Chinese rights to Genfit's liver disease candidate
Terns Pharmaceuticals Inc. (San Mateo, Calif.) licensed rights to elafibranor (GFT505) from Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) to treat non-alcoholic steatohepatitis and primary

Read the full 303 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE